PTC Therapeutics PTCT Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Emflaza | $21.48M-20.6% | $27.06M-23.0% | $35.16M-3.3% | $36.35M-23.9% | $47.79M-5.4% | |
| Other Products | $10.97M+83.2% | $5.99M-39.1% | $9.83M-7.4% | $10.62M-1.9% | $10.82M+230% | |
| Sephience | $124.55M+36.0% | $91.59M+368% | $19.56M— | —— | —— | |
| Translarna | $58.98M+120% | -$294.92M-682% | $50.67M-14.8% | $59.47M-31.0% | $86.15M— | |
| Upstaza And Kebilidi | $9.59M— | —— | —— | —— | $8.66M+105% | |
| Revenue by Geography | ||||||
| All Other Countries Other Than Russia Brazil And United States | $44.6M-6.5% | $47.69M+18.6% | $40.2M+75.6% | $22.9M-60.3% | $57.62M+80.3% | |
| BR | $41.21M+589% | $5.98M-35.1% | $9.22M-77.5% | $40.95M+331% | $9.51M+152% | |
| RU | $3.25M-82.6% | $18.7M-25.5% | $25.11M+38.5% | $18.12M-52.9% | $38.51M-22.4% | |
| US | $136.52M+22.3% | $111.62M+97.8% | $56.42M+55.2% | $36.35M-23.9% | $47.79M-5.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does PTC Therapeutics break its business down?
- PTC Therapeutics (PTCT) reports revenue by product across 6 parts — Emflaza, Other Products, Sephience, Translarna1 and Translarna. Each is extracted from the segment footnotes and tracked over time.
- Where does PTC Therapeutics's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in PTC Therapeutics's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
